Kaleido Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kaleido Biosciences Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11047
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kaleido Biosciences Inc (Kaleido Biosciences) is a developer of human microbiomes for the treatment of infectious, rare genetic, inflammatory, oncology and metabolic diseases. The company’s human microbiome is a metabolic engine which is developed from healthy and diseased humans using various biotechnology techniques. It uses synthetic chemistry to design novel compounds with unique capability to improve specific outputs of the microbiome. Kaleido Biosciences’ novel chemistries are screened in its ex vivo microbiome platform that allows intact human microbiomes to be assayed in a high-throughput laboratory environment. The company discovers new chemistries to modulate the entire metabolic profile of the microbiome. Kaleido Biosciences is headquartered in Bedford, Massachusetts, the US.

Kaleido Biosciences Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Kaleido Biosciences Raises USD101 Million in Series C Venture Financing 10
Kaleido Biosciences Raises Additional Funds through Venture Financing 12
Partnerships 13
Kaleido Biosciences Enters into Agreement with CoreBiome 13
Kaleido Biosciences Inc – Key Competitors 14
Kaleido Biosciences Inc – Key Employees 15
Kaleido Biosciences Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
Aug 21, 2018: Kaleido Biosciences names Alison Lawton as chief executive officer 17
Apr 23, 2018: Kaleido Biosciences Names Joshua Brumm As Chief Financial Officer 19
Mar 26, 2018: Kaleido Biosciences Announces New Leadership Team 20
Jan 03, 2018: Kaleido Biosciences Announces Appointment of Wendy Arnold as Senior Vice President, Human Resources 21
Dec 12, 2017: Kaleido Biosciences Expands Leadership Team with Appointment of Alison Lawton as President and Chief Operating Officer 22
Sep 18, 2017: Kaleido Biosciences Announces Appointment of Mike Bonney as CEO and Completion of Additional Fundraising 23
Other Significant Developments 24
Sep 18, 2017: Flagship Pioneering Unveils Kaleido Biosciences and First Chemistry Platform for Microbiome Health 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kaleido Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kaleido Biosciences Raises USD101 Million in Series C Venture Financing 10
Kaleido Biosciences Raises Additional Funds through Venture Financing 12
Kaleido Biosciences Enters into Agreement with CoreBiome 13
Kaleido Biosciences Inc, Key Competitors 14
Kaleido Biosciences Inc, Key Employees 15

List of Figures
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Kaleido Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Commerzbank AG:戦略・SWOT・企業財務分析
    Commerzbank AG - Strategy, SWOT and Corporate Finance Report Summary Commerzbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Gavis Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析
    Summary Gavis Pharmaceuticals LLC (GAVIS), a subsidiary of Lupin Ltd is a healthcare products provider that develops, markets and distributes tablets and oral solutions. The company offers products such as cetrizine hydrochloride, clobetasol propionate, dexmethylphenidate hydrochloride, dextroamphet …
  • McConnell Dowell Corp Ltd:企業の戦略的SWOT分析
    McConnell Dowell Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Prism Cement Ltd:企業の戦略・SWOT・財務情報
    Prism Cement Ltd - Strategy, SWOT and Corporate Finance Report Summary Prism Cement Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • GW Pharmaceuticals Plc (GWP):製薬・医療:M&Aディール及び事業提携情報
    Summary GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the …
  • Avara Pharmaceutical Services Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Avara Pharmaceutical Services Inc (Avara) is a contract development and manufacturing organization that provides primary formulation and manufacturing, secondary manufacturing and packaging of small molecules. It offers wide range of services such as manufacturing of active pharmaceutical in …
  • DSW Inc.:戦略・SWOT・企業財務分析
    DSW Inc. - Strategy, SWOT and Corporate Finance Report Summary DSW Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • New York Blood Center:製薬・医療:M&Aディール及び事業提携情報
    Summary New York Blood Center (NYBC) is a non-profit healthcare organization that offers blood collection and distribution. The organization's blood products comprise red blood cells, plasma products, platelets, frozen blood and washed products, whole blood and granulocytes. It offers medical servic …
  • Astea International Inc (ATEA):企業の財務・戦略的SWOT分析
    Summary Astea International Inc (Astea) is a technology company that offers end-to-end service management software solutions. The company offers products such as Astea Alliance and FieldCentrix. Its FieldCentrix is used in paper-based operation, optimizes service resources, and provides standardized …
  • Aero Precision Industries, Inc.:企業の戦略・SWOT・財務情報
    Aero Precision Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Aero Precision Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Telus Corp (T):企業の財務・戦略的SWOT分析
    Telus Corp (T) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Achaogen Inc (AKAO):製薬・医療:M&Aディール及び事業提携情報
    Summary Achaogen Inc (Achaogen) is a biopharmaceutical company that discovers, develops and commercializes novel anti bacterials for the treatment of multi-drug resistant and gram-negative infections. The company offers plazomicin for the treatment of serious bacterial infections including urinary t …
  • Windtree Therapeutics Inc (WINT)-医療機器分野:企業M&A・提携分析
    Summary Windtree Therapeutics Inc (Windtree Therapeutics), formerly Discovery Laboratories, Inc. is a specialty biotechnology company. It focuses on the development of novel KL4 surfactant therapies for patients with respiratory diseases and other potential applications. The company’s lead developme …
  • Heartland Consumers Power District:企業の戦略的SWOT分析
    Heartland Consumers Power District - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Asplundh Tree Expert LLC:企業の戦略的SWOT分析
    Asplundh Tree Expert LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Suzlon Energy Ltd (SUZLON):電力:M&Aディール及び事業提携情報
    Summary Suzlon Energy Ltd (Suzlon) is a provider of renewable energy solutions. It offers total solutions package that covers the entire wind energy projects scope. The company provides complete turnkey solutions from design to lifecycle asset management. Suzlon also generates electricity; and sells …
  • Themis Bioscience GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Themis Bioscience GmbH (Themis Bioscience) is a biotechnology company that develops prophylactic vaccines for emerging tropical infections. The company develops emerging and specialist indications and vaccines from preclinical to late-stage clinical development phases. It develops novel vacc …
  • Glen Dimplex Group:企業の戦略的SWOT分析
    Glen Dimplex Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Xvivo Perfusion AB (XVIVO):企業の財務・戦略的SWOT分析
    Summary Xvivo Perfusion AB (Xvivo), a subsidiary of Bure Equity AB is a medical technology company that provides organ transplantation solutions. The company develops organ preservation products such as perfadex and silicone tubing sets and normothermic perfusion products. It offers normothermic per …
  • Biovista Inc-製薬・医療分野:企業M&A・提携分析
    Summary Biovista Inc (Biovista) is a drug development company that provides COSS platform technology support in uncovering non-obvious correlations between drugs. The company’s products are used for the treatment of neurodegenerative diseases, epilepsy, oncology and orphan diseases. It offers servic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆